|
|
| | GSK-5498A Basic information |
| Product Name: | GSK-5498A | | Synonyms: | 2,6-Difluoro-N-[1-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-1H-pyrazol-3-yl]benzamide;GSK-5498A
(GSK5498A);Benzamide, 2,6-difluoro-N-[1-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-1H-pyrazol-3-yl]- | | CAS: | 1253186-49-0 | | MF: | C18H11F6N3O | | MW: | 399.29 | | EINECS: | | | Product Categories: | | | Mol File: | 1253186-49-0.mol |  |
| | GSK-5498A Chemical Properties |
| Boiling point | 403.3±45.0 °C(Predicted) | | density | 1.44±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : ≥ 100 mg/mL (250.44 mM);Water : < 0.1 mg/mL (insoluble) | | form | Solid | | pka | 10.81±0.70(Predicted) | | color | White to off-white |
| | GSK-5498A Usage And Synthesis |
| Definition | ChEBI: GSK-5498A is a member of the class of pyrazoles that is 1H-pyrazole substituted by 2-fluoro-6-(trifluoromethyl)benzyl and (2,6-difluorobenzoyl)amino groups at positions 1 and 3, respectively. It is a inhibitor of Ca(2+) release-activated Ca(2+) (CRAC) channel and inhibits the release of mast cell mediators and T-cell cytokines in human and rat preparations. It has a role as a calcium channel blocker. It is a member of pyrazoles, a secondary carboxamide, a difluorobenzene and a member of (trifluoromethyl)benzenes. |
| | GSK-5498A Preparation Products And Raw materials |
|